About Cynvec

Cynvec was founded in 2004 to develop and commercialize innovative safe and effective cancer treatments based on intellectual property exclusively licensed from New York University (NYU).

Our first product candidate, CYN-101, is a vaccine designed to target ovarian cancer. It utilizes the anti-cancer properties of a bio-engineered form of the naturally-occurring Sindbis virus that expresses a tumor associated antigen derived from the pioneering work of Dr. Daniel Meruelo, a NYU professor who is a leading authority on the Sindbis virus.

Sindbis Virus